Single-Photon Emission Computed Tomography and ^99mTc-Methoxy-Isobutyl-Isonitrile in the Detection and Forecast of Cardiotoxicity of Chemotherapeutic Agents

Abstract:

To compare the possibility of using multiple-gated acquisition (MUGA) scan and Tc-99m MIBI gated SPECT for evaluation and forecast of anthracycline–induced cardiotoxicity. For the treatment of these patients we used doxorubicin in combination with various drugs. All patients were examined by MUGA or Gated SPECT before starting chemotherapy, at 1 hour after the first administration of doxorubicin and after the 4th course. The MUGA and Gated SPECT can be applied with equal efficiency for evaluation of acute and chronic anthracycline–induced cardiotoxicity in patients with malignant tumors. The decrease in LVEF (10% or more) in response to the first dose of doxorubicin can predict the development of chronic cardiotoxicity.

• Periodical: Advanced Materials Research (Volume 1084)
• Pages: 471-475
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1084.471
• Online since: January 2015
• Authors: Vladimir I. Chernov, Tatiana V. Kravchuk, Roman V. Zelchan, Dmitrii M. Podoplekin, Viktor E. Goldberg
• Keywords: ^99mTc-Methoxyisobutyl Isonitrile, Anthracycline-Induced Cardiotoxicity, Gated SPECT

References

[1] M.G. Matysh, T.L. Kravchuk, V.V. Vysotskaya, V.I. Chernov, V.E. Goldberg, Anthracycline-induced cardiotoxicity: mechanisms of development and clinical manifestations, Siberian J. of Oncology 6 (2008) 66-75 (Russian).

[2] L.F. de Geus-Oei, A.M. Mavinkurve-Groothuis, L. Bellersen , M. Gotthardt, W.J. Oyen, L. Kapusta, H.W. van Laarhoven, Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity, J. Nucl. Med. 52 (2011) 560-71.

DOI: 10.2967/jnumed.110.082784

[3] S. Aggarwal, M. D. Pettersen, K. Bhambhani, J. Gurczynski , R. Thomas, T. L'Ecuyer, B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children, J. Pediatr. Blood Cancer 49 (2007) 812-816.

DOI: 10.1002/pbc.21100

[4] V.I. Chernov, A.A. Garganeeva, J.V. Vesnina, Y.B. Lishmanov, Myocardial perfusion scintigraphy in the evaluation of the trimetazidine treatment results in patients with ischemic heart disease, J. Cardiology 41 (8) (2001) 14-16 (Russian).

[5] P.H. Hardenbergh, M.T. Munley, G.C. Bentel, R. Kedem, S. Borges-Neto, D. Hollis, L.R. Prosnitz , L.B. Marks, Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results, Int. J. Radiat. Oncol. Biol. Phys. 49 (2001).

DOI: 10.1016/s0360-3016(00)01531-5

[6] T. Nousiainen, E. Vanninen, E. Jantunen, J. Puustinen, J. Remes, A. Rantala, J. Hartikainen, Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy, J. Int. Med. 249 (2001).

DOI: 10.1046/j.1365-2796.2001.00820.x

[7] R.G. Schwartz, W.B. McKenzie, J. Alexander, P. Sager, A. D'Souza, A. Manatunga, P.E. Schwartz, H.J. Berger, J. Setaro, L. Surkin, Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography, Am. J. Med. 82 (1987).

DOI: 10.1016/0002-9343(87)90212-9

[8] A. Lacko, I. Wlodarska, R. Zymlinski, Cardiac toxicity in cancer therapy, Pol. Merkur. Lekarski. 13 (73) (2002) 79-85.

[9] M.J. Adams, S.E. Lipshultz, Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention, Pediatr. Blood Cancer 44 (2005) 600-606.

DOI: 10.1002/pbc.20352

[10] G.J. Berry, M. Jorden, Pathology of radiation and anthracycline cardiotoxicity, Pediatr. Blood Cancer 44 (2005) 630-637.

DOI: 10.1002/pbc.20346

[11] I.W. Gayed, H.H. Liu, S.W. Yusuf, R. Komaki, X. Wei, X. Wang, J.Y. Chang , J. Swafford, L. Broemeling, Z. Liao, The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer, J. Nucl. Med. 47 (2006).

DOI: 10.1016/j.nuclcard.2006.06.054